84 results about "Disorders pain" patented technology

Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), progesterone (PROG), precursors thereof, metabolites thereof, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.

A controlled release ketoprofen patch for the topical application of ketoprofen is described, in addition to methods of treating inflammatory disorders and pain disorders by the administration of the controlled release ketoprofen patch.

Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.

A method and apparatus for providing occupational therapy using a toothbrush with a palmar grip handle is provided. A plurality of toothbrushes may provide the palmar grip along a portion of the handle, where the palmar grips may be of various sizes. The palmar grip may be substantially spherical in shape, and sized and adapted to stimulate the central nervous system for improving muscle memory, thereby aiding in the rehabilitation of users suffering from central nervous system trauma. The set of toothbrushes may be used in such a manner where a user may become accustom to one size grip before using another size grip. The palmar grip may also be sized and adapted to prevent over-brushing for all users, as well as providing a more comfortable grip for those suffering from hand and join pain disorders, hand-weakness, manual dexterity ailments or fine motor impairments.

Biochemical mediators of inflammation facilitate persistent pain disorder. Treatment follows a multilevel pain gate model to enable site-specific application of appropriate inhibitors that block receptor sites. The result often is the effective treatment of the pain disorder by the administration of lower dosages of the inhibitors than used according to other treatment models.

In one aspect, the present invention discloses combinational compositions for treating users experiencing symptoms associated with a migraine or other central nervous system related pain disorder that can cause or exacerbate nausea and / or vomiting or other central nervous system related pain disorder that can cause or exacerbate nausea and / or vomiting. The combinational composition includes a first pharmaceutical active component for treating pain, and a second pharmaceutical active component for treating nausea and / or vomiting and / or vomiting in a user.

The present invention relates to stable compositions of anti-NGF antibodies, and antigen-binding fragments thereof, and their uses in the prevention and / or treatment of various diseases and disorders in which NGF activity is detrimental, e.g., pain disorders.

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

Treatment of pain disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful in treatment of pain disorders.

Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder in a subject, methods for ameliorating a symptom of schizophrenia, schizoaffective disorder, or other psychotic disorder in a subject, methods for ameliorating a symptom of a depressive disorder in a subject, methods for ameliorating a symptom of bipolar disorder in a subject, methods for ameliorating a symptom of post-traumatic stress disorder or other anxiety disorder in a subject, methods for predicting a predisposition to suicide, suicidal ideation, suicidal behavior, or a combination thereof in a subject, methods for ameliorating a symptom of a pain disorder in a subject, methods for ameliorating a neurodegenerative disorder in a subject, methods for ameliorating a symptom of traumatic brain injury in a subject, methods for ameliorating a sleep disorder in a subject, and methods for improving cognitive functioning in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.

A method for determining the severity of a pain disorder in a subject, comprising the steps of: (i) topically applying an effective amount of menthol or a functional equivalent thereof to the subject's painful area and other locations; and (ii) measuring the response of the subject

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

The invention relates to a back-scraping device with adjustable intensity against medical neuropathic pain diseases. The back-scraping device includes a supporting device, a transverse movement device, a longitudinal movement device, an adjusting device and a fixing device. The transverse movement device is mounted on the supporting device, the longitudinal movement device is mounted at the bottomof the transverse movement device, the bottom of the longitudinal movement device is connected with the top of the adjusting device, and the fixing device is mounted on the adjusting device. According to the back-scraping device, the problems that an existing scraping therapy machine is used for scraping therapy, the mechanical degree is low, the position needs to be adjusted manually, the scraping therapy dynamics is not adjustable, and the angle of a scraping therapy plate cannot be adjusted are solved. A function of scraping therapy with the adjustable intensity can be achieved, and the back-scraping device has the advantages that the mechanical degree is high, the position adjustment is performed automatically, the scraping therapy dynamics can be adjusted, and the angle of the scraping therapy plate can be adjusted.

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

A method for predicting a placebo response in an individual, suffering from or at risk of developing a pain disorder is described. Data is collected from the individual by querying the individual on personality and / or health traits, or performing one or more social learning and / or (bio)physical tests on said individual.The data is used in a mathematical model which attributes a Scoring Factor to the individual. The Scoring Factor is a measure of propensity to raise a placebo response and / or a measure of the intensity of the response for the pain disorder. Tools for implementing the method and preferred uses of the method are described.

A controlled release ketoprofen patch for the topical application of ketoprofen is described, in addition to methods of treating inflammatory disorders and pain disorders by the administration of the controlled release ketoprofen patch.

A toothbrush with a palmar grip handle for dexterity assistance, dexterity rehabilitation and over-brushing prevention is provided. The toothbrush may provide the palmar grip along a portion of the handle. The palmar grip may be substantially spherical in shape, and sized and adapted to stimulate the central nervous system for improving muscle memory, thereby aiding in the rehabilitation of users suffering from central nervous system trauma. The palmar grip may also be sized and adapted to prevent over-brushing for all users, as well as providing a more comfortable grip for those suffering from hand and join pain disorders, hand-weakness, manual dexterity ailments or fine motor impairments.

The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of Alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury. Also provided are methods for ameliorating a sleep disorder; for improving cognitive functioning; for predicting a predisposition to suicide, suicidal ideation, and / or suicidal behavior; and for ameliorating a neurodegenerative disorder. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.

The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

The present invention relates to new compounds of formula (I), wherein P, Q, X<1>, X<2>, X<3>, X<4> X<7>, X<8>, R<1>, R<2>, R<3>, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy, especially for the treatment of mGluR5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.

The embodiments disclosed herein provide methods for inhibiting, reducing and / or treating pain in a subject by administering to a subject in need thereof a pharmaceutical formulation that includes a pharmacologically active compound that is adapted to disrupt PRL signaling in pain neurons. In certain embodiments, the compound is a PRL-R antagonist. In certain embodiments, the compound is adapted to alter the expression of one or more components involved in PRL signaling. Also provided for herein are methods to diagnose a pain disorder in a subject, comprising obtaining a measure of the amount of PRL or PRL mRNA in a biological sample.

Disclosed are compounds of Formula A, or a salt thereof:wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

The invention discloses an external tincture for treating wind-cold-dampness arthralgia. The external tincture is scientific and reasonable in compatibility of prescription, safe and convenient to use, and stable in curative effect. The external tincture has the effects of relieving swelling and pain, promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness, and warming channels and expelling cold, has the characteristics of being less in dosage, and fast and lasting in curative effect, and is mainly used for treating various pain disorders caused by cold, dampness and rheumatism. In the prescription, raw monkshood, spinyleaf pricklyash root, frankincense, periploca forrestii schltr and gaultheria yunnanensis are used for stretching the muscles and activating blood, expelling cold and dredging collaterals, relieving swelling and pain, and warming channels and expelling cold; cinnamon, borneol and shanwei (Chinese character) are used for tonifying fire and helping yang, clearing heat for resuscitation, and cooling blood and relieving pain; propolis is more amazing, can generate complicated chemical reaction after being mixed, soaked and dissolved together with the traditional Chinese medicines, and has the effects of resisting bacteria and diminishing inflammation, and promoting liquid absorption. The propolis is not dissolved into water, so that a layer of hidden protecting film can be quickly formed on a skin surface after the fairy tincture for chilling to the bone and relieving pain is painted. Thus, the pharmaceutical effect of relieving pain can be better developed.